GRZAN Costa Rica Registration Services

1. Key takeaways

GRZAN provides medical device companies entering the Costa Rican market with full-process regulatory services covering 5 stages: classification determination, registration filing, holding and import arrangements, post-registration changes and renewal, and post-market vigilance and verification response. The current main regulation RTCR 505:2022 divides devices into Clase 1 to Clase 4; Clase 1 is exempt from sanitary registration (Article 2.4) but five obligations still apply, while Clase 2 to 4 require sanitary registration before manufacture, import, sale or distribution (Article 9). Registration is valid 5 years (Article 15), and renewal requires 11 items of documentation (Article 16). Our delivery model is to break the provisions into executable document lists and timelines, not a generic template.

• Classification determination is the entry point for all downstream work and the step where errors are most costly.
• Clase 1 exemption from registration does not mean exemption from obligations: import, labelling, advertising, vigilance and control all continue.
• The 2024 amendment changed the feasible CLV sourcing space through the new 4.7, 10.20, 17.3 and 18.11.4.
• The two hard thresholds for foreign entities are the domestic legal representative and the power of attorney.
• Spanish filing and document legalisation are the longest-lead items and should be scheduled at project start.
• Post-market is not the end point: vigilance, 19 change categories, renewal, labelling and advertising, and verification run on an annual compliance calendar.

2. Legal basis

The service scope above maps onto RTCR 505:2022 (approved by DE 43902-S of 30 November 2022), the 2024 amendment, and DE 37988-S.

3. Expert insights

Insight one: Classification determination is the entry point for all downstream work, and the step where errors are easiest. The Costa Rican basis is the rule list of Annex A, not the industry-circulated description of four tiers from low to high risk. For example, rule 2 a) classifies devices for the oral cavity to pharynx, nasal cavity to pharynx, or ear canal to tympanic membrane as Clase 1; rule 3 b) classifies reusable surgical instruments as Clase 1; rule 8 classifies radiation devices as Clase 3, radiographic as Clase 2 and mammography as Clase 3; rule 14 a) b) classifies animal-origin or recombinant DNA products as Clase 4. Once classification is wrong, the whole downstream dossier is mismatched.

Insight two: Clase 1 exemption from registration is not exemption from obligations. Article 2.4 states expressly that Clase 1 is exempt from sanitary registration while import, labelling, advertising, vigilance and control obligations continue to apply; Article 22.2 further allows the Ministry of Health to require Clase 1 products to submit materials to determine their true risk classification. Treating Clase 1 as nothing to manage is the commonest misjudgment we see.

Insight three: The 2024 amendment changed the feasible space for CLV plans. The new 4.7 allows the CLV to be issued by the authority of the holder’s country, the holder’s subsidiary’s country or the parent company’s subsidiary’s country (the subsidiary must be legally established there), resolving the old problem of not obtaining a CLV where the product is not sold in the manufacturing country; the new 10.20 adds the declaration letter route where the CLV omits the holder’s name; the new 17.3 and 18.11.4 close off misuse of the relief channels. The package directly affects group structure planning.

Insight four: The two hard thresholds for foreign entities are the domestic legal representative and the power of attorney. Article 10.3 requires foreign holders to appoint a legal representative residing in Costa Rica; Article 11.9 requires a power of attorney (poder). Both must be designed in step with the commercial arrangements among holder, manufacturer and importer, or the certificate and the trade flow will diverge.

Insight five: Filing language and document legalisation are the longest stages. Article 10.13 requires filing documents in Spanish, with official translations (traducción oficial) for official or legal documents; Article 10.17 requires foreign documents to be legalised or apostilled with notarised certification of digital signatures. Their lead times often exceed technical document preparation and belong in the plan at project launch.

Insight six: Post-market is not the end point. Article 21 requires technovigilance under DE 39342-S; Article 18 governs the 19 categories of change; Articles 15 and 16 govern the 5-year validity and 11 renewal items; Articles 19 and 20 govern labelling and advertising; Article 22 governs verification. We build the annual compliance calendar on these five lines, not on official notices.

4. Practical recommendations

• Start with a written classification determination: compare the product’s intended use and structural features against the Annex A rules one by one, and issue a written determination citing the rules as the basis for the document list.
• Build the document package by class: Clase 2 under Article 11 (including the 12 technical specification items and 6 medical specification items); Clase 3 adds the six clinical evidence items of Article 12.2; Clase 4 adds risk analysis, post-market literature and animal-origin biosafety certificates. Never reuse packages across classes.
• Design the CLV plan early: choose the issuing country under the 2024 new 4.7 in light of the group structure and confirm the subsidiary’s legal establishment; where the CLV omits the holder’s name, arrange the new 10.20 declaration letter and its notarisation in parallel.
• Run language and legalisation in parallel: official Spanish translation, legalisation or apostille of foreign documents, and notarised certification of digital signatures proceed alongside technical document preparation to compress the timeline.
• Build the holding and import structure once, correctly: design in step the holder (titular del producto), the domestic legal representative, the power of attorney, and the operating permit status of importers and authorised distributors, so the certificate and trade flow do not diverge.
• Deliver an annual compliance calendar: renewal under Articles 15 and 16, changes under Article 18, label and advertising review under Articles 19 and 20, technovigilance under Article 21, verification materials under Article 22.
• Track regulatory changes: monitor the national BPM regulation (Transitorio IV), the recognition list, the fee schedule and Regístrelo portal form versions, updating dossiers when they change.

5. Verification checklist

• □ A written classification determination with cited rule numbers (Annex A) has been obtained
• □ The document list for the class is confirmed (Articles 11, 12 or 13)
• □ The CLV issuing country is chosen and the subsidiary’s legal establishment confirmed
• □ Official Spanish translation and legalisation or apostille of foreign documents are in hand
• □ The domestic legal representative is appointed and the power of attorney ready (Articles 10.3 and 11.9)
• □ The importer and authorised distributors hold valid operating permits
• □ Label design (18 mandatory items) and the supplementary label plan are complete under Article 19
• □ An annual calendar exists for renewal (11 items, Article 16) and changes (19 categories, Article 18)
• □ A technovigilance process is in place (Article 21 and DE 39342-S)
• □ Change alerts for the BPM regulation and recognition list are in place

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Costa Rican market. Our team manages Ministry of Health (Ministerio de Salud) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com